Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

3 Underrated Growth Stocks That Look Like Great Buys Heading Into 2026
3 Underrated Growth Stocks That Look Like Great Buys Heading Into 2026

Are you looking for a top growth stock to buy heading into 2026? Although valuations are high for many stocks, there are some potential deals still out there right now.

Three stocks that haven't

Why Voyager Technologies Stock Zoomed 8% Higher on Wednesday
Why Voyager Technologies Stock Zoomed 8% Higher on Wednesday

Voyager Technologies (NYSE: VOYG) took its investors on the kind of voyage they enjoy on Wednesday. The space and defense company's stock took off that day, closing the trading session more than 8%

2 Cruise Line Stocks Are Moving in Different Directions
2 Cruise Line Stocks Are Moving in Different Directions

There's an old saying that a rising tide lifts all ships. Ironically enough, the adage doesn't apply to cruise line stocks. Norwegian Cruise Line (NYSE: NCLH) is once again the worst-performing

2 Pharmaceutical Stocks to Buy at a Discount
2 Pharmaceutical Stocks to Buy at a Discount

If you see news about the pharmaceutical industry today and it isn't directly about GLP-1 weight loss drugs, it's likely to include at least a mention of this new class of medications. GLP-1 drugs

Can ASTS Stock Beat the Market in 2026?
Can ASTS Stock Beat the Market in 2026?

AST SpaceMobile (NASDAQ: ASTS) was a bad investment from 2020 to the start of 2024. The stock woefully underperformed the S&P 500 during that stretch and went from $20 per share to $2 per share

2 Stocks Up Over 600% in the Past 3 Years With More Room to Run
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run

Those who had the foresight to invest in Summit Therapeutics (NASDAQ: SMMT) and Madrigal Pharmaceuticals (NASDAQ: MDGL) three years ago are sitting pretty right now. Both companies have soared over

Down 50%, Should You Buy the Dip on Pfizer?
Down 50%, Should You Buy the Dip on Pfizer?

Pfizer (NYSE: PFE) is deeply unloved today. There are a couple of reasons for this that are important, but the big story revolves around the company's drug portfolio. With three drugs facing patent

Why a $27 Million Buy Signals New Confidence in Weatherford Stock
Why a $27 Million Buy Signals New Confidence in Weatherford Stock

Summit Street Capital Management established a new position in Weatherford International (NASDAQ:WFRD), adding 398,661 shares valued at an estimated $27.3 million during the third quarter, according

Signet Jewelers Gains New $25 Million Institutional Backer — Is the Stock a Buy?
Signet Jewelers Gains New $25 Million Institutional Backer — Is the Stock a Buy?

On November 14, New York City-based Summit Street Capital Management disclosed a new position in Signet Jewelers (NYSE:SIG), acquiring 264,054 shares valued at $25.3 million, according to its latest

Why a Value Fund Has a $29 Million Bet on Core Natural Resources Stock
Why a Value Fund Has a $29 Million Bet on Core Natural Resources Stock

New York City-based Summit Street Capital Management increased its stake in Core Natural Resources (NYSE:CNR) by 81,170 shares in the third quarter, adding approximately $10.4 million in position

Is Kulicke and Soffa Stock a Buy Even as One Fund Dumps a $10 Million Stake?
Is Kulicke and Soffa Stock a Buy Even as One Fund Dumps a $10 Million Stake?

New York City-based Summit Street Capital Management fully exited its position in Kulicke and Soffa Industries, Inc. (NASDAQ:KLIC), reducing holdings by 281,812 shares during the quarter and

Trump Approved Nvidia's H200 Exports, but China's Limits Could Change Everything
Trump Approved Nvidia's H200 Exports, but China's Limits Could Change Everything

After months of uncertainty, President Donald Trump announced that the U.S. government would permit Nvidia (NASDAQ: NVDA) to sell its H200 processors to China. Trump announced the decision in a post

Here's 1 Major Catalyst Behind Merck Stock's Recent 3.8% Bump
Here's 1 Major Catalyst Behind Merck Stock's Recent 3.8% Bump

After lagging the market over the past couple of years, Merck (NYSE: MRK) has experienced a slight rebound in the last month, thanks to several positive developments. The stock has increased by 20%

Why Intel Is Massively Outperforming Nvidia and AMD This Year
Why Intel Is Massively Outperforming Nvidia and AMD This Year

In today's video, I discuss recent updates affecting Intel (NASDAQ: INTC), Nvidia (NASDAQ: NVDA), Advanced Micro Devices (NASDAQ: AMD), and other artificial intelligence (AI) stocks. To learn more,

AMD's CEO Makes an Interesting Prediction About Competitive AI Chips
AMD's CEO Makes an Interesting Prediction About Competitive AI Chips

In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD) and other artificial intelligence (AI) stocks. To learn more, check out the short video, consider

Nvidia Stock Pops After President Trump OKs Sales of New H200 AI Chips to China
Nvidia Stock Pops After President Trump OKs Sales of New H200 AI Chips to China

Nvidia (NASDAQ: NVDA) stock gained 2.3% in after-hours trading on Monday, following President Donald Trump's reportedly posting on Truth Social that the U.S. government will allow Nvidia to export

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares

Foresite Capital Management IV, LLC disclosed a new stake in Cytokinetics (NASDAQ:CYTK), adding 458,295 shares valued at $25.19 million as of Sept. 30, 2025. The move was detailed in a quarterly

VALBIOTIS SA: Valbiotis announces completion of recruitment for the Cardio-Liver clinical study conducted with TOTUM•448 for metabolic liver diseases (MASLD)
VALBIOTIS SA: Valbiotis announces completion of recruitment for the Cardio-Liver clinical study conducted with TOTUM•448 for metabolic liver diseases (MASLD)
VALBIOTIS SA: Valbiotis announces completion of recruitment for the Cardio-Liver clinical study conducted with TOTUM•448 for metabolic liver diseases (MASLD)
EQS-News: Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS)
EQS-News: Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS)
EQS-News: Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS)
EQS-News: Evotec closes sale of Just – Evotec Biologics’ Toulouse site to Sandoz
EQS-News: Evotec closes sale of Just – Evotec Biologics’ Toulouse site to Sandoz
EQS-News: Evotec closes sale of Just – Evotec Biologics’ Toulouse site to Sandoz
This Artificial Intelligence (AI) Infrastructure Stock Could Be the Nvidia of 2026
This Artificial Intelligence (AI) Infrastructure Stock Could Be the Nvidia of 2026

For the last three years, one piece of hardware has continually earned credit for the rise of generative artificial intelligence (AI) applications: the semiconductor. Naturally, investors sought

Vertex Stock: Why One Fund Lifted Its $94.3 Million Position Even as Shares Sank
Vertex Stock: Why One Fund Lifted Its $94.3 Million Position Even as Shares Sank

On November 14, California-based Tensile Capital Management disclosed a buy of 160,559 shares of Vertex (NASDAQ:VERX) in the third quarter. Despite the expanded stake, the market value of the

Why One Value Fund Has a $101 Million Bet on Indivior Stock Amid a 212% Surge
Why One Value Fund Has a $101 Million Bet on Indivior Stock Amid a 212% Surge

New York City-based Newtyn Management reported a buy of nearly 1.6 million additional Indivior PLC shares, increasing its position by an estimated $62.8 million in the third quarter, according to a

3 Nuclear Energy Stocks to Buy Before 2026
3 Nuclear Energy Stocks to Buy Before 2026

With energy demand surging globally, nuclear power is one energy source that checks all of the boxes. That's because it provides reliable, carbon-free power, providing consistent baseload energy

Merck's Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy?
Merck's Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy?

Merck (NYSE: MRK) has taken its shareholders on a wild ride of late -- from last March's record high of more than $130 to this May's low near $76 back to its current price of just a little more than